Trial Sites Will Receive Support from UK Health System

BETHESDA, Md., April 16, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that the Company’s Phase III clinical
trial for Glioblastoma multiforme (GBM) brain cancer has been
“adopted” as a national priority trial in the UK, under the
“adoption” program managed by the National Institute for Health
Research (NIHR), which is part of the UK’s National Health
System.  This “adoption” of the Company’s Phase III trial
constitutes a significant validation, and also carries with it
resources and operational support for the trial sites.

The NIHR maintains a “portfolio” of clinical trials that have
been “adopted” as high priorities for the UK.  In order to be
selected for the NIHR Portfolio, a proposed clinical trial must go
through multiple layers of review and evaluation.  The
evaluation includes the potential significance of the new medical
technology being tested, the quality of the trial design, the
feasibility of the trial, and numerous other factors. 

Trials that are selected (“adopted”) for inclusion in the NIHR Portfolio are monitored closely by
the NIHR and the trial sites receive several types of financial and operational support. For
example, the NIHR provides resources and funding for additional staff (e.g., nurses) at the trial
sites to help accelerate the trial. The NIHR also oversees the performance of the sites, and
imposes penalties on the sites for shortfalls such as lags in enrollment.

“We understand that it is relatively rare for a small biotech company to have its clinical trial
‘adopted’ into the NIHR portfolio, especially a Phase III trial,” noted Linda Powers, CEO of NW
Bio. “This important validation of our trial is an exciting development, and the extra resources
and support from the NIHR to the trial sites will be very helpful in accelerating our trial.”

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
United States and Europe.  The Company has a broad platform
technology for DCVax dendritic cell-based vaccines.  The
Company’s lead program is a 312-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM).  GBM is the most
aggressive and lethal form of brain cancer.  The Company also
previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer, and clearance from the FDA for Phase
I/II trials in multiple other cancers.  The Company also
conducted a Phase I/II trial with DCVax for metastatic ovarian
cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.  Words such as “expect,” “believe,”
“intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and
similar expressions are intended to identify forward-looking
statements.  Actual results may differ materially from those
projected in any forward-looking statement.  Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company’s ability to raise additional capital, risks related to the
Company’s ability to enroll patients in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company’s products will
demonstrate safety and efficacy.  Additional information on
these and other factors, including Risk Factors, which could affect
the Company’s results, is included in its Securities and Exchange
Commission (“SEC”) filings.  Finally, there may be other
factors not mentioned above or included in the Company’s SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement.  You should
not place undue reliance on any forward-looking statements. 
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.